

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.

**Tit Transthyretin cardiac amyloidosis beyond advanced age: two cases in  
unusually young patient**

**Authors:** Krzysztof Badura, Aleksander Baszkowski, Maciej Nadel, Joanna Kurzaj,  
Aleksander Misiewicz, Jarosław Drożdż

**Article type:** Clinical image

**Received:** April 28, 2026.

**Revision accepted:** June 25, 2026.

**Published online:** July 6, 2026.

**ISSN:** 1897-9483

Pol Arch Intern Med.

doi:10.20452/pamw.17340

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License ([CC BY 4.0](https://creativecommons.org/licenses/by/4.0/)), allowing anyone to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, including commercial purposes, provided the original work is properly cited.

## **Transthyretin cardiac amyloidosis beyond advanced age: two cases in unusually young patient**

Krzysztof Badura\*, Aleksander Baszkowski\*, Maciej Nadel, Joanna Kurzaj, Aleksander Misiewicz, Jarosław Drożdż

Second Department of Cardiology, Second Chair of Cardiology, Medical University of Lodz, Łódź, Poland

\* KB and AB contributed equally to this work.

**Correspondence to:** Maciej Nadel, MD, PhD, Second Department of Cardiology, Second Chair of Cardiology, Medical University of Lodz, ul. Pomorska 251, 92–213 Łódź, Poland, phone: +48 42 201 43 08, email: [maciej.nadel@umed.lodz.pl](mailto:maciej.nadel@umed.lodz.pl)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a chronic disease characterized by extracellular deposition of misfolded amyloid fibrils in the myocardium [1]. Recent studies indicate that ATTR-CM is underdiagnosed and may be associated with different cardiac diseases including heart failure with preserved ejection fraction, aortic stenosis, and left ventricular (LV) hypertrophy [1,2]. ATTR-CM is typically diagnosed among advanced-age patients, what was confirmed by the first Polish multicenter study on patients with ATTR-CM, where the median age at diagnosis was 76 years (interquartile range: 69–82) [3]. We present two cases involving younger individuals, highlighting that ATTR-CM should also be considered outside the typical age range.

A 51-year-old male with the suspicion of hypertrophic cardiomyopathy, a history of heart failure with reduced ejection fraction, hyperlipidemia, arterial hypertension, hip arthroplasty 15 years prior to hospitalization, and a history of nicotine abuse presented to the Department of Cardiology due to acute decompensated heart failure. The electrocardiogram (ECG) revealed lowered voltage in all limb leads and pseudoinfarct pattern in leads III and aVF (Figure 1A). Transthoracic echocardiography (TTE) has shown a mildly reduced LV ejection fraction of 42% accompanied by a concentric LV hypertrophy, right ventricular hypertrophy, and ground-glass myocardial appearance (Figure 1B). LV global longitudinal strain was reduced (-5.9%) with an apical sparing pattern (Figure 1C). Cardiac magnetic resonance demonstrated abnormal gadolinium kinetics, suggesting myocardial amyloid infiltration.

Second patient, a 56-year-old male with suspected hypertrophic cardiomyopathy and a history of arterial hypertension, singular premature ventricular contractions, benign prostatic hyperplasia and post-Lyme syndrome was referred for advanced cardiovascular evaluation. Moreover, the patient underwent surgery for bilateral carpal tunnel syndrome at the age of 45 and a surgical treatment of a traumatic tear of the left biceps brachii tendon, associated with a rotator cuff injury. The ECG revealed low QRS voltages in the limb leads (Figure 1D). TTE revealed preserved LV systolic function with concomitant LV hypertrophy and grade 3 diastolic dysfunction (Figure 1E). Additionally, right ventricular hypertrophy was present. Furthermore, LV global longitudinal strain was reduced (-13.7%) showing apical sparing pattern (Figure 1F). Cardiac magnetic resonance has shown subendocardial late gadolinium enhancement (Figure 1G).

Both patients had chronically elevated levels of troponin T and N-terminal pro-B-type natriuretic peptide. Additionally, for both cases  $^{99m}\text{Tc}$  hydroxymethylene diphosphonate planar scintigraphy complemented by single-photon emission computed tomography imaging was performed according to current recommendations of the Section of Nuclear Medicine of the

Polish Cardiac Society and the Polish Nuclear Medicine Society [4] revealed Perugini grade 3 myocardial uptake, which confirmed the diagnosis of amyloid cardiomyopathy (Figure 1H). In both patients, light-chain cardiac amyloidosis was excluded, as serum free light chain assay, serum and urine protein electrophoresis with immunofixation were negative. For both presented cases, next-generation sequencing of the coding sequences and flanking intronic regions of the TTR gene revealed no pathogenic or likely pathogenic variants and no variants of uncertain significance, confirming the diagnosis of wild-type ATTR-CM

In both patients, guideline-directed therapy for heart failure in the course of cardiac amyloidosis was introduced, and both patients received tafamidis as a targeted treatment of ATTR-CM.

Presented cases emphasize the importance of screening for ATTR-CM if the red flags are present – the younger age should not delay the diagnosis, as delayed initiation of targeted treatment is associated with unfavorable outcomes [1]. Diagnosis of ATTR-CM should include general evaluation, ECG, TTE, laboratory tests with the focus on red flags presented in the European Society of Cardiology guidelines [5], as well as bone scintigraphy, hematological tests and, if needed, CMR and/or endomyocardial biopsy. Proper identification of the red flags may alter the diagnostic pathway and prompt the diagnosis of a specific cause of cardiomyopathy, which remains crucial to improve outcomes.

### **Article information**

**Acknowledgments:** The authors thank the Department of Nuclear Medicine, Medical University of Lodz for acquisition, processing and interpretation of scintigraphy imaging data.

**Funding:** No external funding was received.

**Conflict of interest:** None declared.

**AI statement:** Artificial intelligence was not used in preparation of this manuscript.


Open access: This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing anyone to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, including commercial purposes, provided the original work is properly cited.

How to cite: Badura K, Baszkowski A, Nadel M, et al. Transthyretin cardiac amyloidosis beyond advanced age: two cases in unusually young patient. *Pol Arch Intern Med.* 2026; XX: 17340. doi:10.20452/pamw.17340

## References

- 1 Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J.* 2021; 42: 1554-1568.
- 2 Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Eur Heart J.* 2017; 38: 2879-2887.
- 3 Gawor-Prokopczyk M, Grzybowski J, Lipowska M, et al. Multicenter study of patients with transthyretin cardiac amyloidosis in Poland: Clinical characteristics, genotyping, electrocardiographic features, outcome predictors and tafamidis treatment outcomes. *Pol Heart J.* 2026; 84: 37-46.
- 4 Holcman K, Dziuk M, Grzybowski J, et al. The scintigraphic diagnosis of cardiac amyloidosis. An expert opinion endorsed by the Section of Nuclear Medicine of the Polish Cardiac Society and the Polish Nuclear Medicine Society. *Nucl Med Rev Cent East Eur.* 2022; 25: 142-147.

5 Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44: 3503-3626.



**Figure 1** A-C – non-invasive cardiological assessment of the 51-year-old patient; A – baseline resting electrocardiogram showing low QRS voltage in all limb leads and pseudoinfarct pattern in leads III and aVF; B – transthoracic echocardiography (TTE) revealing thickened interatrial septum (arrow), thickened valves, granular sparkling; C – TTE revealing reduced global longitudinal strain ( $-5.9\%$ ) with the apical sparing strain pattern; D-F – non-invasive cardiological assessment of the 56-year-old patient; D - baseline resting electrocardiogram showing lowered voltage of QRS complexes in leads I, II, III, aVR, aVL, and aVF; E - TTE

revealing thickened interatrial septum (arrow), thickened valves, granular sparkling; **F** – TTE revealing reduced global longitudinal strain (–13.7%) with the apical sparing pattern; **G** – cardiac magnetic resonance of the 56-year-old patient showing subendocardial and intramural (arrow) late gadolinium enhancement; **H** – fusion image of <sup>99m</sup>Tc hydroxymethylene diphosphonate scintigraphy and computed tomography of the 51-year old patient revealing elevated heart muscle uptake (arrow)

**Short title:** Transthyretin cardiac amyloidosis in two unusually young patients